Abeona received a permanent HCPCS J‑code, J3389, for its autologous gene‑therapy product ZEVASKYN, effective January 1, 2026. The code provides a unique identifier that simplifies billing for qualified treatment centers and payers.
The J‑code follows FDA approval of ZEVASKYN on April 29, 2025, and the start of commercial launch in Q3 2025. By reducing administrative burden and supporting consistent reimbursement rates, the code is expected to accelerate adoption of the therapy.
Abeona’s Q2 2025 financial results showed a net income of $108.8 million, largely driven by the sale of a priority review voucher. The company projects profitability in early 2026, contingent on uptake and reimbursement for ZEVASKYN.
The permanent J‑code is anticipated to streamline payer processes, set a precedent for other cell and gene therapies, and support Abeona’s plan to scale manufacturing to treat up to 10 patients per month by mid‑2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.